| Literature DB >> 31319649 |
Yasser K Rashed1, Mohamed El-Guindi2.
Abstract
BACKGROUND: The esophagus is the most common part of gastrointestinal (GI) tract at the risk of stricture. Benign disorders are the leading causes of narrowing. Caustic ingestion is the most common cause of esophageal stricture in children, especially in developing countries. Clinical responses to the topical application of Mitomycin C in various medical procedures have been reported.Entities:
Keywords: Corrosive esophagitis; Esophageal stricture; Mitomycin C
Year: 2019 PMID: 31319649 PMCID: PMC6801201 DOI: 10.3345/kjp.2018.07157
Source DB: PubMed Journal: Korean J Pediatr ISSN: 1738-1061
Description of the studied cases
| Case No. | Age (mo) | Sex | Length of stricture (mm) | Cause | Diagnosis | Diameter (mm) | No. of dilatation setting before MC | Interval between 2 endoscopic settings (wk) | No of dilatation with MC | Interval between endoscopic setting (MC) (wk) | Response | Route of application | Complications |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 60 | F | 110 | Corrosive | Gastrografin and upper GI endoscopy | 1 | 75 | 2–3 | 4 | 4 | Good | Spray | No |
| 2 | 56 | M | 70–75 | 1 | 45 | 2–3 | 2 | 4 | Excellent | Spray | No | ||
| 3 | 36 | M | 13–15 | 1 | 9 | 2–4 | 2 | 4 | Excellent | Spray | No | ||
| 4 | 42 | M | 30–35 | 2 | 7 | 2–4 | 2 | 4 | Excellent | Spray | No | ||
| 5 | 72 | F | 30–35 | 5 | 3 | 2 | 1 | 0 | Excellent | Spray | No | ||
| 6 | 50 | F | 35–40 | Reflux | 3 | 11 | 4 | 1 | 0 | Excellent | Pledget | No | |
| 7 | 35 | F | 15–20 | Corrosive | 1 | 22 | 2–4 | 3 | 3-4 | Excellent | Pledget | No | |
| 8 | 75 | M | 40–45 | 2 | 18 | 4–6 | 2 | 4 | Excellent | Pledget | No | ||
| 9 | 41 | M | 25–30 | 1 | 12 | 4 | 2 | 4 | Excellent | Pledget | No | ||
| 10 | 70 | F | 45–50 | 4 | 8 | 4 | 2 | 4 | Excellent | Pledget | No | ||
| 11 | 35 | M | 40 | Unknown | 1 | 4 | 4 | 1 | 0 | Excellent | Pledget | No | |
| 12 | 40 | M | 30 | Corrosive | Upper GI endoscopy | 3 | 4 | 3 | 2 | 8 | Excellent | Pledget | No |
| 13 | 144 | F | 30 | Sclero | 2 | 5 | 2 | 1 | 0 | Excellent | Pledget | No | |
| 14 | 60 | M | 50 | Corrosive | 3 | 5 | 2–4 | 3 | 8-12 | Excellent | Pledget | No | |
| 15 | 22 | F | 30 | 1 | 10 | 2–4 | 3 | 8-12 | Excellent | Pledget | No | ||
| 16 | 16 | M | 30 | Unknown | 4 | 4 | 2 | 2 | 8-12 | Excellent | Pledget | No | |
| 17 | 23 | F | 25 | Corrosive | 2 | 4 | 2–4 | 3 | 8-12 | Excellent | Pledget | No | |
| 18 | 72 | F | 40 | 1 | 12 | 2–4 | 4 | 8-12 | Excellent | Pledget | No | ||
| 19 | 36 | F | 30 | Unknown | 1 | 3 | 2–4 | 1 | 0 | Excellent | Pledget | No | |
| 20 | 168 | M | 70 | Corrosive | 1 | 16 | 2 | 5 | 5 | Good | Pledget | No | |
| 21 | 28 | M | 30 | 1 | 6 | 2 | 3 | 4 | Excellent | Pledget | No | ||
| 22 | 30 | M | 24 | 2 | 3 | 2 | 2 | 4 | Excellent | Spray | No | ||
| 23 | 40 | M | 35 | 2 | 3 | 2 | 2 | 4 | Excellent | Spray | No | ||
| 24 | 42 | F | 40 | Unknown | 1 | 3 | 2 | 1 | 6 | Excellent | Spray | No | |
| 25 | 54 | F | 10 | 2 | 6 | 2 | 2 | 4 | Excellent | Spray | No | ||
| 26 | 39 | M | 25 | Corrosive | 2 | 4 | 2 | 2 | 4 | Excellent | Spray | No | |
| 27 | 44 | M | 10 | 2 | 7 | 2 | 2 | 4 | Excellent | Spray | No | ||
| 28 | 40 | F | 10 | 5 | 7 | 2 | 2 | 4 | Excellent | Spray | No | ||
| 29 | 50 | M | 15 | 5 | 7 | 2 | 2 | 4 | Excellent | Spray | No | ||
| 30 | 56 | M | 10 | 5 | 5 | 2 | 2 | 4 | Excellent | Spray | No |
MC, Mitomycin C; GI, gastrointestinal; Sclero, sclerotherapy.